Mode
Text Size
Log in / Sign up

Implementation bundle reduces guideline-discordant prolonged antimicrobial use in patients undergoing cardiovascular implantable electronic device proceduresNew Strategy Reduces Improper Antibiotic Use After Heart Device Surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider an I/D bundle with audit-feedback to reduce guideline-discordant prolonged antimicrobial use after CIED procedures.

This guideline-based implementation and effectiveness study evaluates the impact of an implementation/deimplementation (I/D) bundle on antimicrobial practices for patients undergoing cardiovascular implantable electronic device (CIED) procedures. The bundle included blended facilitation, local champions, provider education, and access to locally-customed audit-feedback data regarding benchmarking, infections, and antimicrobial harms such as acute kidney injury and Clostridiodes difficile infections.

The study found that rates of guideline-discordant prolonged antimicrobial use fell in intervention sites compared to controls (OR, 0.16; 95% CI, 0.12-0.21). While the initial period showed a trend toward reduced composite antimicrobial harms (OR, 0.59; 95% CI, 0.34, 1.02; p=0.059), the sustainment period showed a statistically significant decrease in composite harm (aOR, 0.57; 95% CI, 0.34-0.91; p=0.02). No significant change was observed in CIED infection rates (OR, 0.96; 95% CI, 0.48-1.93; p=0.91).

Authors noted that practices learned from other settings acted as barriers to change. The findings suggest that audit-feedback regarding patient-level harms of guideline-discordant care is an effective strategy for reducing low-value care. However, the study is a non-randomized quasi-experimental design, and the initial reduction in composite harm did not reach statistical significance.

How this fits prior evidence

This finding addresses a gap in optimizing antimicrobial stewardship for patients undergoing cardiovascular implantable electronic device procedures. It specifically addresses the management of antimicrobial use in high-risk surgical settings, though it does not directly relate to the previously covered topics of microbiota-directed therapies for atopic dermatitis, corticosteroid use in pediatric pneumonia, or the impact of multimorbidity on sepsis outcomes.

Researchers studied how to improve the way hospitals manage antibiotics for patients undergoing cardiovascular implantable electronic device (CIED) procedures. They compared two groups of hospitals. One group used a specific bundle of tools, including staff education, local champions, and data feedback to help doctors follow medical guidelines more closely. The other group did not use this bundle.

The study of over 7,500 procedures showed that the hospitals using the bundle significantly reduced the use of antibiotics that went against standard guidelines. While the rate of infections did not change, there was a trend toward fewer complications from antibiotics, such as kidney issues or allergic reactions. During a follow-up period, the bundle also showed a significant decrease in these types of harms.

Because this was a quasi-experimental study and not a randomized trial, the results should be viewed as a promising step in improving hospital quality. The study suggests that providing doctors with specific data about the risks of certain antibiotics can help them make safer choices. Patients should talk to their doctors about how these safety measures are used during their specific procedures.

What this means for you:
A specific education and feedback bundle helped hospitals reduce the use of unnecessary antibiotics after heart surgery.

Common questions

What is the main benefit of the new antibiotic bundle?

The bundle was designed to reduce the use of antibiotics that did not follow medical guidelines. In the study, hospitals using this method saw a significant drop in guideline-discordant antibiotic use. This approach aims to improve the quality of care and reduce the risks associated with unnecessary medication for patients getting heart device implants.

Does this new method reduce infection rates?

The study found no significant change in the rates of infections for patients receiving heart devices. While the goal of the program was to improve safety, the specific data showed that the infection rates remained stable compared to the group that did not use the intervention bundle.

Are there fewer side effects from antibiotics with this method?

The study showed a trend toward fewer complications from antibiotics, such as kidney issues or allergic reactions, in the first phase. During the follow-up period, there was a statistically significant decrease in these types of harms for patients in the intervention group.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedSep 2026
View Original Abstract ↓
Effective de-implementation approaches to reduce low-value or harmful care are limited. Prolonged antimicrobial use after skin closure is ineffective and increases harm but is nonetheless common following cardiovascular implantable electronic device (CIED) procedures. The aim of this quasi-experimental Implementation/Effectiveness study was to use an implementation/de-implementation (I/D) bundle of strategies to promote de-implementation of guideline-discordant prolonged antimicrobial use and improve outcomes. Hybrid III Implementation/Effectiveness study grounded in learning/unlearning theory and guided by the integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) framework with a non-randomized parallel group trial design (3 intervention and 8 control sites) over a 12-month period with an additional 12-months of follow up to assess sustainment. The I/D bundle included: blended facilitation, local champions, provider education, and access to locally-customized audit-feedback data about facility-level guideline compliance with benchmarking, CIED infections, and antimicrobial harms (acute kidney injury, allergic events, Clostridiodes difficile infections). Implementation outcomes were assessed quantitatively using a difference-in-differences model and qualitatively; clinical outcomes were assessed quantitatively. 2,293 CIED procedures were performed at the 3 intervention sites and 5,273 at the 8 matched control sites. Following I/D bundle intervention, rates of guideline non-compliance fell in the intervention sites but not the controls (OR, 0.16, 95% CI, 0.12–0.21). There was no change in CIED infections following the intervention (OR, 0.96, 95% CI, 0.48–1.93, p = 0.91) and a trend toward a reduction in composite antimicrobial harms (OR = 0.59; 95% CI: 0.34, 1.02, p-value = 0.059). Improvements were sustained during the 12-month period after active implementation and associated with a decrease in composite harm (aOR = 0.57; 95% CI: 0.34–0.91, p = 0.02). Strategies identified as effective for promoting de-implementation included education, locally-customized dashboard audit-feedback data with benchmarking to high-performing sites and feedback about both harm and benefit, blended facilitation, and provider’s readiness to change. Review and updating of hospital factors that promote sustainment of ineffective care, such as automated order sets, were also important. Practices learned and introduced from other practice settings were important barriers to change. The I/D bundle that included audit-feedback about patient-level harms of guideline discordant care was an effective strategy for reducing low-value care and improving quality.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.